5β-Androsterone Acetate is an intermediate in the synthesis of 3-keto-5β-abiraterone (K170985), a metabolite of abiraterone (A108490) which is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17).3-keto-5β-abiraterone is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.